LivingGLP1
Descriptive only

Kidney composite including albuminuria or smaller eGFR declines

Type 2 diabetes (adults)

longest follow-upCause specific hazardsEach dose separatelyHazard ratio
1
Randomized trials
2
Treatments
0
Participants
2
Trial arms

In plain language

No network meta-analysis was fitted here. The protocol requires at least two trials forming a connected network; this outcome has 1 trial. The trial data below are shown as reported.

Network of trials

Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.
DULA_SC_1p5MG_QWPLACEBO
Node area shows participants; line width shows trials comparing two treatments directly. Blue: GLP-1 receptor agonist containing treatments; grey: comparators. Hover over or tab to a node or line for details.

Baseline characteristics of the trials

The baseline value of each effect modifier or prognostic factor that applies here, per trial: mean or percent over arms, weighted by the number randomized. A note under a value names a stand in (a median for a mean, 100 minus the male share, Asian subgroup rows, an all Asian site list); "not reported" means no source of the trial prints it.
Baseline effect modifiers and prognostic factors per trial
TrialKidney function (eGFR) (mL/min/1.73 m2)
prognostic factor, effect modifier; 1 of 1
Albuminuria (mg/g)
prognostic factor; 1 of 1
REWIND
S000147
76.91.84

Comparability of the trials

Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.

No comparability concerns were found.

Comparability items per trial
Trialtime weeksanalysis setdefinitioninstrumentadjudicatedproportion methodintercurrent events (discontinuation)intercurrent events (rescue)blindingfundingstart yearEligibility
REWIND365.26randomizedserious renal adverse event linked to acute renal failure by database searchnot statednot statednot statednot statednot stateddouble_blindindustry2011age 50 or older with T2D; HbA1c 9.5 percent or less; BMI 23 or more; CV disease or risk factors

Trial data

What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the hazard ratio on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.
Trial data entering this analysis
TrialArmTreatmentWeekDataValueSEEvents / NFlagsSource
REWINDA1PLACEBO365.26contrast, hrR0018694:Table 2
REWINDA2DULA_SC_1p5MG_QW365.26contrast, hr-0.3010.062R0018694:Table 2

Rerun this analysis yourself

Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.

Open in the NMA lab